Pediatrix Medical Group, Inc. $MD Stock Holdings Lifted by Teacher Retirement System of Texas

Teacher Retirement System of Texas boosted its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 58.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 244,269 shares of the company’s stock after purchasing an additional 90,413 shares during the period. Teacher Retirement System of Texas owned 0.28% of Pediatrix Medical Group worth $4,092,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. American Century Companies Inc. increased its stake in shares of Pediatrix Medical Group by 28.6% in the second quarter. American Century Companies Inc. now owns 1,931,867 shares of the company’s stock worth $27,722,000 after acquiring an additional 430,029 shares during the last quarter. Ameriprise Financial Inc. lifted its position in Pediatrix Medical Group by 175.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company’s stock worth $10,683,000 after acquiring an additional 474,186 shares during the last quarter. Qube Research & Technologies Ltd boosted its stake in Pediatrix Medical Group by 2.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 735,526 shares of the company’s stock valued at $10,555,000 after purchasing an additional 14,596 shares during the period. Nomura Holdings Inc. lifted its holdings in shares of Pediatrix Medical Group by 121.4% during the second quarter. Nomura Holdings Inc. now owns 576,730 shares of the company’s stock worth $8,276,000 after buying an additional 316,274 shares during the last quarter. Finally, Bridgeway Capital Management LLC raised its stake in Pediatrix Medical Group by 3.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 574,885 shares of the company’s stock valued at $8,250,000 after purchasing an additional 20,433 shares during the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Stock Down 3.7%

NYSE:MD opened at $20.55 on Wednesday. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The stock has a 50-day moving average price of $22.31 and a two-hundred day moving average price of $18.60. Pediatrix Medical Group, Inc. has a 1 year low of $11.84 and a 1 year high of $24.99. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of 10.81 and a beta of 0.73.

Pediatrix Medical Group (NYSE:MD) last announced its earnings results on Monday, November 3rd. The company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.46 by $0.21. Pediatrix Medical Group had a net margin of 8.44% and a return on equity of 20.45%. The firm had revenue of $492.88 million for the quarter, compared to the consensus estimate of $476.45 million. During the same period last year, the company posted $0.44 EPS. The business’s quarterly revenue was down 3.6% on a year-over-year basis. As a group, equities analysts expect that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current year.

Insider Activity

In other news, Director Laura A. Linynsky sold 10,000 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $21.65, for a total transaction of $216,500.00. Following the completion of the transaction, the director directly owned 32,232 shares of the company’s stock, valued at $697,822.80. This represents a 23.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mark S. Ordan sold 23,000 shares of Pediatrix Medical Group stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $22.41, for a total value of $515,430.00. Following the completion of the sale, the chief executive officer directly owned 302,805 shares in the company, valued at approximately $6,785,860.05. This represents a 7.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 43,478 shares of company stock worth $972,924 over the last three months. Corporate insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

MD has been the subject of several recent research reports. Zacks Research cut Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Friday, January 23rd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Monday, December 29th. Truist Financial raised their price target on Pediatrix Medical Group from $17.00 to $24.00 and gave the company a “hold” rating in a report on Monday, November 10th. UBS Group raised their price objective on shares of Pediatrix Medical Group from $16.50 to $23.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. Finally, Wall Street Zen upgraded Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 4th. One research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $21.00.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.